MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Clinical trials for MALIGNANT PERIPHERAL NERVE SHEATH TUMOR explained in plain language.
Never miss a new study
Get alerted when new MALIGNANT PERIPHERAL NERVE SHEATH TUMOR trials appear
Sign up with your email to follow new studies for MALIGNANT PERIPHERAL NERVE SHEATH TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for rare sarcomas
Disease control CompletedThis study looked at adding the drug pazopanib to standard radiation or chemoradiation before surgery for patients with certain soft tissue sarcomas. The goal was to see if the combination is safe and helps shrink tumors more effectively. About 140 adults and children with newly …
Matched conditions: MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail shows promise for rare sarcomas
Disease control CompletedThis study tested a combination of two drugs, cobimetinib and atezolizumab, in children and adults with advanced soft tissue sarcoma that has spread. The goal was to see if the combo is safe and can stop tumors from growing. About 229 people took part, and researchers measured ho…
Matched conditions: MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Personalized chemo shows promise against rare sarcomas
Disease control CompletedThis Phase 3 trial tested whether giving chemotherapy based on the specific type of soft tissue sarcoma works better than a one-size-fits-all approach. 550 adults with high-risk sarcomas in the arms or trunk were randomly assigned to standard chemo or a chemo regimen matched to t…
Matched conditions: MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Phase: PHASE3 • Sponsor: Italian Sarcoma Group • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC